1. Home
  2. GIB vs WAT Comparison

GIB vs WAT Comparison

Compare GIB & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CGI Inc.

GIB

CGI Inc.

HOLD

Current Price

$90.59

Market Cap

19.5B

ML Signal

HOLD

Logo Waters Corporation

WAT

Waters Corporation

HOLD

Current Price

$383.45

Market Cap

23.0B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
GIB
WAT
Founded
1976
1958
Country
Canada
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Laboratory Analytical Instruments
Sector
Consumer Discretionary
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
19.5B
23.0B
IPO Year
N/A
1995

Fundamental Metrics

Financial Performance
Metric
GIB
WAT
Price
$90.59
$383.45
Analyst Decision
Hold
Buy
Analyst Count
3
15
Target Price
$117.00
$388.67
AVG Volume (30 Days)
314.8K
527.7K
Earning Date
01-28-2026
11-04-2025
Dividend Yield
0.49%
N/A
EPS Growth
0.55
3.82
EPS
5.28
10.88
Revenue
$11,424,213,683.00
$3,105,638,000.00
Revenue This Year
$8.52
$7.96
Revenue Next Year
$3.31
$6.32
P/E Ratio
$17.18
$35.43
Revenue Growth
8.43
6.90
52 Week Low
$84.00
$275.05
52 Week High
$122.79
$423.56

Technical Indicators

Market Signals
Indicator
GIB
WAT
Relative Strength Index (RSI) 57.30 50.66
Support Level $89.13 $385.08
Resistance Level $92.32 $397.55
Average True Range (ATR) 1.52 9.42
MACD 0.21 -3.19
Stochastic Oscillator 57.85 7.46

Price Performance

Historical Comparison
GIB
WAT

About GIB CGI Inc.

CGI is a Canada-based IT-services provider with an embedded position in North America and Europe. The company is one of the major IT suppliers to different levels of government around the world. It offers a broad portfolio of services such as consulting, systems integration, application maintenance, and business process services to governments and the private sector. With offices in over 40 countries, CGI follows a balanced global delivery model with most consultants in client proximity.

About WAT Waters Corporation

Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.

Share on Social Networks: